Company
EUREKA
HARNESSING THE EVOLUTIONARY POWER OF T CELLS TO FIGHT SOLID TUMORS
Also known as Eureka Therapeutics, Eureka Therapeutics, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Eureka Therapeutics, Inc.
- eurekatherapeutics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative technology platforms that can access cancer-specific targets and harness the evolutionary power of T cells for the treatment of solid tumors and other malignancies.
Funding snapshot
- Total raised
- $113MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round2023-05-17
Funding rounds
- Round, 2023
- 2023-05-17
- Round, 2019
- $45M2019-12-16, SEC form D sold, 20 investors
- Round, 2018
- $20M2018-06-04, SEC form D sold, 2 investors
- Round, 2016
- $26.6M2016-12-13, SEC form D sold, 40 investors
- Round, 2014
- $21M2014-08-20, SEC form D sold, 28 investors
Loading relationship preview